ストックスクリーナーアプリを入手
3.31
5.08%
0.16
アフターアワーズ：
3.41
0.10
+3.02%
前日終値:
$3.15
開ける：
$3.15
24時間の取引高:
1.17M
Relative Volume:
0.75
時価総額：
$167.55M
収益：
-
当期純損益:
$-297.11M
株価収益率:
-0.6378
EPS:
-5.19
ネットキャッシュフロー:
$-216.95M
1週間 パフォーマンス:
+37.92%
1か月 パフォーマンス:
-32.17%
6か月 パフォーマンス:
-66.05%
1年 パフォーマンス:
-65.77%
1日の値動き範囲:
$3.0249
$3.34
1週間の範囲:
$2.21
$3.78
52週間の値動き範囲:
$2.21
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
名前
Phathom Pharmaceuticals Inc
セクター
電話
(877) 742-8466
住所
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
3.31 | 167.55M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 開始されました | Stifel | Buy |
| 2024-01-05 | 繰り返されました | Needham | Buy |
| 2023-08-09 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-05-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2021-05-12 | アップグレード | Goldman | Sell → Neutral |
| 2021-02-17 | 開始されました | BMO Capital Markets | Outperform |
| 2021-02-02 | 開始されました | Guggenheim | Buy |
| 2020-06-26 | ダウングレード | Goldman | Neutral → Sell |
| 2019-11-20 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Goldman | Neutral |
| 2019-11-19 | 開始されました | Jefferies | Buy |
| 2019-11-19 | 開始されました | Needham | Buy |
すべてを表示
Phathom Pharmaceuticals Inc (PHAT) 最新ニュース
(PHAT) Proactive Strategies - news.stocktradersdaily.com
Phathom pharmaceuticals outlines VOQUEZNA expansion targets and cost-saving measures for profitability by 2026 - MSN
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT) - MSN
Phathom Pharmaceuticals surges 50% following large insider purchase - MSN
Phathom Pharmaceuticals (PHAT) Shares Surge After Board Member's Large Purchase - GuruFocus
Insider Buying: Asit Parikh Acquires Additional Shares of Phathom Pharmaceuticals Inc (PHAT) - GuruFocus
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price Target - Yahoo Finance
Phathom Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations - Yahoo
H.C. Wainwright cuts Phathom Pharma stock target to $20, keeps Buy rating - Investing.com Canada
Phathom Pharmaceuticals (PHAT) Price Target Lowered by Goldman Sachs | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Target Price Lowered by Guggenheim | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Maintains Buy Rating as Price Tar - GuruFocus
Phathom Pharmaceuticals (PHAT) Maintains Buy Rating as Price Target Drops | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Price Target Reduced by Guggenhei - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals (PHAT) Price Target Reduced by Guggenheim | PHAT Stock News - GuruFocus
PHAT Faces Price Target Cut Amidst Restructuring Efforts | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Phathom Pharmaceuticals Eyes Profitability Amid Growth - TipRanks
Phathom Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Phathom Pharmaceuticals Grants 186,508 Shares Package to New Sales Chief in Strategic Hire - Stock Titan
Phathom (PHAT) Implements Strategic Shift for Long-Term Growth | - GuruFocus
Phathom Pharmaceuticals Q1 2025 Earnings: EPS Matches Estimates at -$1.18, Revenue Falls Short at $28.5 Million - GuruFocus
Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News
Phathom Pharmaceuticals stock hits 52-week low at $3.8 By Investing.com - Investing.com India
Phathom Pharmaceuticals to Report First Quarter 2025 Financial R - GuruFocus
Phathom Pharmaceuticals stock hits 52-week low at $3.8 - Investing.com
Earnings call transcript: Phathom Pharmaceuticals beats Q1 2025 earnings expectations - Investing.com
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Res - GuruFocus
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Q1 2025 Financial Results - TradingView
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Phathom (PHAT) Implements Strategic Shift for Long-Term Growth | PHAT Stock News - GuruFocus
BlackRock, Inc. Reduces Stake in Phathom Pharmaceuticals Inc. - GuruFocus
Phathom Pharmaceuticals Inc [PHAT] CFO and CBO makes an insider sale of 3,678 shares worth $16740.0. - knoxdaily.com
Uncovering the Potential of Phathom Pharmaceuticals Inc (PHAT) Stock - investchronicle.com
Upward Trajectory: Phathom Pharmaceuticals Inc (PHAT) Posts a Slidee, Closing at 4.11 - DWinneX
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting - GlobeNewswire
Groundbreaking GERD Treatment VOQUEZNA: First Real-World Data Release Coming at DDW 2025 - Stock Titan
Phathom Pharmaceuticals (PHAT) to Release Earnings on Thursday - Defense World
Phathom Pharmaceuticals Inc [PHAT] Shares Fall Approximately -55.18% Over the Year - knoxdaily.com
Was Phathom Pharmaceuticals Inc (PHAT)’s session last reading good? - uspostnews.com
Geode Capital Management LLC Acquires 155,577 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals Inc (PHAT) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):